November 4, 2014 | The central nervous system drug developer NeuroDerm filed a revised prospectus with the US Security and Exchange Commission for an IPO on NASDAQ. The company reportedly hopes to raise between $60-82 million at a company values of between $236-290 million, after money. Jefferies and Cowen & Company are the joint bookrunners for the offering, with Oppenheimer and Roth Capital as secondary underwriters. When NeuroDerm completes its IPO, the company join the Israeli record set on Wall Street with 10 biomedical companies trading publicly. NeuroDerm is developing a transdermal delivery system for drugs for the treatment of Parkinson’s disease.